Inhibikase Therapeutics (IKT) Payables (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Payables of $1.6 million for Q1 2026, down 6.19% year-over-year from $1.7 million in Q1 2025, and up 37.07% quarter-over-quarter from $1.2 million in Q4 2025.
Inhibikase Therapeutics (IKT) Payables (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Payables for 7 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 6.19% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 6.19% YoY), while the FY2025 annual figure was $1.2 million, up 22.8% from the prior year.
- Payables climbed to $1.6 million in Q1 2026 per IKT's latest filing, from $1.2 million in the prior quarter.
- Across five years, Payables topped out at $21.8 million in Q1 2023 and bottomed at $620528.0 in Q3 2025.
- Historically, Payables has averaged $2.9 million across 5 years, with a median of $1.3 million in 2024.
- On a YoY basis, Payables climbed as much as 2599.29% in 2023 and fell as far as 83.21% in 2023.
- Inhibikase Therapeutics' Payables stood at $1.2 million in 2022, then tumbled by 43.82% to $646767.0 in 2023, then soared by 45.81% to $943019.0 in 2024, then rose by 22.8% to $1.2 million in 2025, then jumped by 37.07% to $1.6 million in 2026.
- Business Quant data shows IKT's Payables at $1.6 million in Q1 2026, $1.2 million in Q4 2025, and $620528.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 991,720.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 991,720.00 |
| Mar 31, 2026 | 1.59 Mn |
| Dec 31, 2025 | 1.16 Mn |
| Sep 30, 2025 | 620,528.00 |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 1.69 Mn |
| Dec 31, 2024 | 943,019.00 |
| Sep 30, 2024 | 2.53 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | 3.80 Mn |
| Dec 31, 2023 | 646,767.00 |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | 754,146.00 |
| Mar 31, 2023 | 21.76 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Sep 30, 2022 | 781,223.00 |
| Jun 30, 2022 | 4.49 Mn |
| Mar 31, 2022 | 806,196.00 |
| Dec 31, 2021 | 1.34 Mn |
| Sep 30, 2021 | 2.71 Mn |